⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 26, 2024CureusOpen Access

Real-World Evidence on Use of Ceftazidime-Avibactam in the Management of Gram-Negative Infections: A Retrospective Analysis

Subhash Todi Prachee Sathe V Ramasubramanian S. Subramanian Deepak Talwar Parikshit Prayag Polati Vishnu Rao Kirti Sabnis Shweta Kamat Akshata Mane Harish Thanusubramanian

View Full Paper

Ask AI

Bookmark

Share

Abstract

There is limited real-world data from India examining the treatment characteristics, safety, and efficacy of ceftazidime-avibactam against Gram-negative organisms especially multidrug-resistant pathogens including carbapenem-resistant

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Todi et al. (2024) studied this question.

synapsesocial.com/papers/68e5743bb6db643587514a59 https://doi.org/10.7759/cureus.70234

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Real-world Evidence on Use of Ceftazidime-Avibactam in the Management of Gram-Negative Infections: A Retrospective Analysis2024
2Effectiveness of Ceftazidime-Avibactam in Gram-Negative Nosocomial Pneumonia: A Real-World Study in India2024 · 2 citations
3Drug utilization evaluation of ceftazidime-avibactam in a tertiary care hospital2024
4Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant Organisms: A Prospective, Observational, Single-Center Study2025 · 1 citations
5P-1323. Ceftazidime–avibactam in real-world clinical practice: results from a single centerOriginal Research · 2026